ArticleCureus2026
Evaluation of Blood Pressure Variability With Clevidipine Infusion in Patients With Acute Cerebrovascular Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood pressure variability (BPV) has been associated with worse outcomes in patients with acute cerebrovascular diseases, and acute hypertension is routinely treated with intravenous antihypertensives. Objective: The goal of this study was to determine if clevidipine infusions can safely and effectively reach blood pressure targets and maintain blood pressure control without undesirable variability. Methods: This was a prospective, single-arm, observational study. We enrolled a convenience sample of adult patients hospitalized for acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), or posterior reversible encephalopathy syndrome (PRES) who required clevidipine for blood pressure control within 24 hours of symptom onset. The primary efficacy outcome was systolic BPV during the first hour. The primary safety outcomes were acute neurological decline and acute kidney injury (AKI). Secondary outcomes were BPV within 24 hours, time to blood pressure goal, and the association between BPV and early neurologic decline and AKI. Results: Thirty patients were enrolled with a median age of 64 (58, 77), and most were White (83.3%) and females (57%). The most common primary diagnosis was ICH (63%). The median (IQR) first systolic blood pressure (SBP) reading was 170 (153, 193) mmHg. The median (interquartile range (IQR)) time from clevidipine initiation to blood pressure goal was 20 (10, 28) minutes. The mean systolic BPV in the first hour, as measured by standard deviation (SD), was 17.2 (9.3). At 24 hours, the mean systolic BPV by SD was 16.4 (5.6). Six patients (20%) experienced AKI, and 11 (37%) experienced a neurologic decline. Conclusion: This study describes BPV observations with clevidipine in cerebrovascular disease. This study is limited by the small sample size and observational design. Comparative studies evaluating the effects of different antihypertensive strategies on BPV are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.